You are here

A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

Last updated on May 9, 2018

FOR MORE INFORMATION
Study Location
Seishinkai Inoue Hospital
Itoshima, Fukuoka, Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Pneumococcal Vaccines, Pneumococcal Conjugate Vaccine
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
65+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

1. Healthy Japanese male and female adults aged 65 years old and older at time of
enrollment. Subjects with preexisting stable disease, defined as disease not requiring
significant change in therapy or hospitalization for worsening disease 12 weeks before
receipt of the study vaccine, are eligible.

2. Male and female subjects of childbearing potential must agree to use a highly
effective method of contraception throughout the study or for at least 28 days after
the last dose of the study vaccine whichever is longer.

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

1. History of severe adverse reaction including hypersensitivity such as anaphylaxis
associated with a vaccine or vaccine component.

2. Previous vaccination with any licensed or experimental pneumococcal vaccine.

3. Documented Streptococcus pneumoniae infection within the past 5 years.

4. Residence in a nursing home, long-term care facility, or other institution or
requirement of semiskilled nursing care.

NCT01646398
Pfizer
Completed
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
A Phase 3 Trial Evaluating the Safety, Tolerability, and Immunogenicity of a 13-valent Pneumococcal Conjugate Vaccine in Japanese Elderly Adults Aged 65 Years Old and Older
A Phase 3, Randomized, Modified Double-Blind, Active-Controlled Trial Evaluating The Safety, Tolerability, And Immunogenicity Of A 13-Valent Pneumococcal Conjugate Vaccine In Japanese Elderly Adults Aged 65 Years Old And Older Who Are Naive To Pneumococcal Vaccine
The purpose of this study is to evaluate the safety, tolerability and immunogenicity of a single dose of 13-valent pneumococcal conjugate vaccine compared to a single dose of 23-valent pneumococcal polysaccharide vaccine in Japanese adults aged 65 years old and older.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
  • Pneumococcal Vaccines
  • Pneumococcal Conjugate Vaccine
  • Biological: 13-valent pneumococcal conjugate vaccine
    A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
    Other Name: 13vPnC
  • Biological: 23-valent pneumococcal polysaccharide vaccine
    A single dose (0.5 mL) will be administered intramuscularly into the deltoid muscle at visit 1.
    Other Name: 23VPS
  • Experimental: >= 65-year age group-13vPnC
    Intervention: Biological: 13-valent pneumococcal conjugate vaccine
  • Active Comparator: >= 65-year age group-23vPS
    Intervention: Biological: 23-valent pneumococcal polysaccharide vaccine
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
764
October 2012
October 2012   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Healthy Japanese male and female adults aged 65 years old and older at time of enrollment. Subjects with preexisting stable disease, defined as disease not requiring significant change in therapy or hospitalization for worsening disease 12 weeks before receipt of the study vaccine, are eligible.
  2. Male and female subjects of childbearing potential must agree to use a highly effective method of contraception throughout the study or for at least 28 days after the last dose of the study vaccine whichever is longer.

Exclusion Criteria:

  1. History of severe adverse reaction including hypersensitivity such as anaphylaxis associated with a vaccine or vaccine component.
  2. Previous vaccination with any licensed or experimental pneumococcal vaccine.
  3. Documented Streptococcus pneumoniae infection within the past 5 years.
  4. Residence in a nursing home, long-term care facility, or other institution or requirement of semiskilled nursing care.
Sexes Eligible for Study: All
65 Years and older   (Adult, Senior)
Yes
Contact information is only displayed when the study is recruiting subjects
Japan
 
 
NCT01646398
B1851088
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2013

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now